E-LIB Suche - Ergebnisse für: Peyrin-Biroulet, L.

1

P1036 Persistence of biologics and advanced small molecules..:

Parigi, T L ; Massimino, L ; Carini, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1868-i1869 , 2024

Link: https://doi.org/10.1093/..

2

P710 Prevalence, Characteristics and Management of Patients..:

Parigi, T L ; Massimino, L ; Carini, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1339-i1340 , 2024

Link: https://doi.org/10.1093/..

3

OC.03.8: EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WIT..:

Kaser, A. ; Sands, B.E. ; Protic, M....
Digestive and Liver Disease. 56 (2024) - p. S137-S138 , 2024

Link: https://doi.org/10.1016/..

4

BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLO..:

Sands, B.E. ; D'haens, G. ; Clemow, D.B....
Digestive and Liver Disease. 56 (2024) - p. S121-S122 , 2024

Link: https://doi.org/10.1016/..

5

P985 Efficacy and safety of de-escalation from 50 mg to 25 ..:

Dulai, P ; Sands, B E ; Danese, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1787-i1787 , 2024

Link: https://doi.org/10.1093/..

6

OC.13.2: EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL ..:

Magro, F. ; Pai, R.K. ; Kobayashi, T....
Digestive and Liver Disease. 56 (2024) - p. S193 , 2024

Link: https://doi.org/10.1016/..

7

P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hyper..:

Verstockt, B ; Vermeire, S ; Peyrin-Biroulet, L...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i400-i401 , 2024

Link: https://doi.org/10.1093/..

8

P678 Long-term efficacy, safety and health-related quality ..:

Feagan Senior Scientific Officer, B G ; Matsuoka, K ; Rogler, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1288-i1289 , 2024

Link: https://doi.org/10.1093/..

9

P683 Economic impact of achieving mucosal healing on UC-rel..:

Peyrin-Biroulet, L ; Ungaro, R ; Rubin, D T...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1298-i1299 , 2024

Link: https://doi.org/10.1093/..

10

DOP71 Efficacy of once-daily, orally administered obefazimo..:

Vermeire, S ; Danese, S ; Peyrin-Biroulet, L...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i203-i204 , 2024

Link: https://doi.org/10.1093/..

11

P772 Comprehensive disease control in patients with Ulcerat..:

Schreiber, S W ; Feagan, B G ; Vermeire, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1440-i1442 , 2024

Link: https://doi.org/10.1093/..

12

P1010 Guselkumab improves abdominal pain and bowel urgency ..:

Rubin, D ; Panés, J ; Feagan, B...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1825-i1826 , 2024

Link: https://doi.org/10.1093/..

13

P927 Long-term outcomes of risankizumab in Crohn's disease:..:

Fumery, M ; Caron, B ; Hébuterne, X...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1686-i1686 , 2024

Link: https://doi.org/10.1093/..

14

P280 Comparative responsiveness of disease activity indices..:

Solitano, V ; Panaccione, R ; Sands, B E...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i647-i648 , 2024

Link: https://doi.org/10.1093/..

15

P857 Effectiveness and safety of subcutaneous infliximab in..:

Andre, M ; Kirchgesner, J ; Laharie, D...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1587-i1587 , 2024

Link: https://doi.org/10.1093/..